1. Scrip

Korean Tagrisso Launch Builds On Extensive Local Data

 
• By Jung Won Shin

AstraZeneca's Tagrisso has debuted in South Korea, raising hopes and treatment options for certain types of lung cancer patients, but the product will face immediate local direct competition from Hanmi’s recently launched rival olmutinib.

SEOUL - South Korea has become the fifth market for AstraZeneca PLC's first-in-class lung cancer drug Tagrisso (osimertinib) after the US, Europe, Japan and Israel, following approval by the Ministry of Food and Drug Safety for EGFR T790M mutation-positive progressive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who have undergone EGFR-TKI therapy.

AstraZeneca Korea said the drug had been launched without reimbursement initially, but that it is seeking to apply for national health insurance coverage

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.